trial

Dextromethorphan as an Augmentation Agent in Treatment-resistant Schizophrenia

NCTId NCT05944510
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 40 (actual)
Sponsored by All India Institute of Medical Sciences, Bhubaneswar
Primary completion 2024-10-15
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
40 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2023-08-31
Primary completion
2024-10-15
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
Dextromethorphan

Sponsors

All India Institute of Medical Sciences, BhubaneswarLead Sponsor

Investigators

1
DEBASISH HOTA, D.M.Study Chair

Sites

1 total
Bhubaneswar, India

Facts & assertions

4 sourced
Enrollment
40
Phase
PHASE4
Primary Completion Date
2024-10-15
Status
COMPLETED
relationships
The graph out of here
drug
Dextromethorphan
drug
lead_sponsor
All India Institute of Medical Sciences, Bhubaneswar
company
indication
Treatment Resistant Schizophrenia
indication
Schizophrenia, Treatment-Resistant
indication
investigator
DEBASISH HOTA, D.M.
person